APC

Jhajjar, India
Jhajjar, India
SEARCH FILTERS
Time filter
Source Type

Tampa, FL, July 20, 2017 (GLOBE NEWSWIRE) -- Cancer diagnostics and pathology workflow solution provider Inspirata®, Inc. announced today that it is exhibiting in Booth #2 at the Association of Pathology Chairs (APC) Annual Meeting at the Omni Shoreham in Washington, DC, July 24-28. “Inspirata is pleased to once again be the Diamond Sponsor at APC’s annual meeting and we’re looking forward to helping the association celebrate its Jubilee Anniversary marking 50 years that the association has been contributing to advancements in the field of pathology,” says Inspirata CEO Satish Sanan. Inspirata is working at the forefront of technological advancements the field of pathology with the implementation of an end-to-end digital pathology workflow solution at The Ohio State University’s James Cancer Center. While at APC next week, Inspirata will host a Corporate Workshop titled “Ushering in a New Era in Pathology: Going Digital Today” on Thursday, July 27th from 3:00 – 4:30 in the Congressional Room at the Omni Shoreham Hotel. The workshop’s headline speakers include two pathology leaders from The James who will explain how this groundbreaking initiative is unlike any other and how they gained institutional buy-in to pursue for such a long-term and far-reaching project. The workshop also will provide a behind-the-scenes look at Inspirata’s ongoing digital pathology workflow implementation at The James, including around-the-clock scanning operations for both retrospective and prospective histopathology slides; digital pathology cockpits that the institution’s pathologists will use for primary diagnosis and remote consultations; and an array of tools for decision support, image analysis and a unique predictive assay. Beyond these pathology-specific activities, Inspirata’s engagement at The James is a major collaborative effort that also encompasses planning and implementation services; operational management and staffing; the development of additional cockpits for research, operations and a multidisciplinary tumor board; and a variety of sponsored research projects. A cumulative benefit of these activities will be the creation of a cancer information data trust or digital archive that can be used for clinical activities as well as cost-of-care analyses, health management, education, research operations, biopharma discovery and much more. “While rooted in digital pathology, our 10-year engagement at The James encompasses a new vision—not just for pathology—but for the entire cancer center enterprise,” explains Sanan. “We look forward to laying out the blueprint so that others can follow in the footprints of the pioneers at The James.” The Association of Pathology Chairs (APC) is a non-profit society, which serves as the voice of academic departments of Pathology in the U.S., Canada and Puerto Rico. APC exists to provide leadership and advocacy for the dynamic discipline of Pathology and to enable academic departments to meet the demands of their three missions: medical education, research and practice. The APC provides education, training, information resources and networking opportunities for chairs, residency program directors (through PRODS), medical student educators (through UMEDS), department administrators (through PDAS), and program coordinators (through GMEAS). For more information, please visit http://www.apcprods.org/. Inspirata®, Inc. offers the most comprehensive cancer diagnostics workflow solution available for precision diagnosis today. The solution, which employs a unique “solution-as-a-service” business and delivery model, accelerates anatomic and molecular pathology workflows and facilitates whole slide imaging and image analytics, prognostic and predictive assays, remote consultations and tumor boards. This comprehensive solution includes an Enterprise Service Bus (ESB) to help to solve interoperability issues and a Natural Language Processing Engine (NLP) for structuring data. Inspirata amalgamates this structured data into a central multi-institutional and multi-modal big data cancer repository for clinical, research and educational purposes. Its use will extend to physicians, patients, researchers and pharma among others. This comprehensive solution facilitates a modern precision diagnosis to build a strong foundation for precision medicine. For more information, please visit www.inspirata.com or contact info@inspirata.com. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c385d383-632e-415c-b891-010a220a04eb A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/000ef9ca-4011-4cb8-8592-a280b2fab076


News Article | July 18, 2017
Site: www.marketwired.com

VANCOUVER, BC--(Marketwired - July 18, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) ( : 0E8) a biotechnology company focused on developing superior targeted protein therapeutics is pleased to announce a collaboration with the National Research Council of Canada (NRC). Through this arrangement both parties have forged a strategic relationship to further the development of antibody-drug conjugates (ADCs). Through recently signed collaborations, APC's efforts are centered on antibody candidates that will be linked to drugs or toxins for the purpose of treating advanced solid tumors such as ovarian cancer, breast cancer, and non-small cell lung cancer, areas of ongoing therapeutic need in a more effective way. "APC and the NRC will join forces to accurately evaluate the extent to which a drug (or toxin) has been attached to an antibody, validating our proprietary linker technology," stated Allen Krantz, APC's Founder and Chief Science Officer. "Scaling up and testing of the drug-linked candidates we produce, in cell models, will determine their potential as therapies and move APC one step closer to a commercialization." The NRC's expertise in antibody structure, antibody-drug conjugate development, biomanufacturing, analytics, cell-based assays and in vitro and in vivo pharmacology will help APC further evaluate the site-selective conjugation using APC's linker technology and progress the development of cancer therapeutic candidates from APCs partners. This work is being conducted as part of the NRC's Biologics and Biomanufacturing program, aiming toward better health outcomes for Canadians with cancer. "We are pleased to apply the NRC's expertise in advanced analytics of ADCs to further the development of new cancer treatments, and we look forward to working with APC on this project," says Jennifer Hill, Team Leader, Mass Spectrometry and Nuclear Magnetic Resonance Analytics, at the NRC. Advanced Proteome Therapeutics Corporation (APC) is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 11, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC)(FRANKFURT:0E8) is pleased to report that it has completed its previously announced rights offering (the "Rights Offering"). Under the Rights Offering, on July 10, 2017, 7,136,216 units of the Corporation (the "Units") were distributed at a price of $0.06 per Unit for gross proceeds to the Corporation of $428,172.96. Each Unit consists of one common share of the Corporation (a "Common Share") and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"), with each Warrant entitling its holder to purchase one additional Common Share at a price of $0.10 per Common Share until July 10, 2018. Upon closing of the Rights Offering, there are 133,821,634 Common Shares outstanding and 21,786,773 Common Shares reserved for issuance, including 11,961,773 common share purchase warrants (3,568,108 of which were issued pursuant to the Rights Offering). The Corporation intends to use the net proceeds of which will be used for debt repayment as well as working capital. To the knowledge of the Corporation, after reasonable inquiry, directors, officers and other insiders of the Corporation exercised their basic subscription privileges to acquire an aggregate of 6,250 Units under the Rights Offering, and additional subscription privileges to acquire an aggregate of 83,333 Units under the Rights Offering, representing total subscription proceeds of approximately $5,374.98. To the knowledge of the Corporation, after reasonable inquiry, no person that was not an insider became an insider of the Corporation as a result of the Rights Offering. The Corporation will pay solicitation fees in the aggregate amount of $16,701.52, representing $0.0026 for each Unit subscribed for, to members of Investment Industry Regulatory Organization of Canada (IIROC) which exercised rights on behalf of their clients. Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategies, plans or intentions. In particular, this news release contains forward-looking statements including, but not limited to, statements regarding the use of proceeds from the Rights Offering. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


News Article | June 1, 2017
Site: www.marketwired.com

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 1, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC)(FRANKFURT:0E8) is pleased to announce that it will conduct a rights offering to raise gross proceeds of up to $1,900,281 (the "Rights Offering"). Under the Rights Offering, the Company will be offering transferable rights (the "Rights") to holders of its common shares (the "Common Shares") resident in Canada at the close of business on June 7, 2017 (the "Record Date"), on the basis of one Right for each Common Share held. Four Rights will entitle the holder to subscribe for one unit of the Company (a "Unit") at a subscription price of $0.06 per Unit, which represents a discount to the closing price of the Common Shares on the TSX Venture Exchange (the "Exchange") on May 31, 2017. No fractional Units will be issued. Each Unit will consist of one Common Share and one-half of one common share purchase warrant, with each whole warrant exercisable into one Common Share for a period of 12 months following the closing of the Rights Offering (the "Closing Date") at a price of $0.10 per Common Share. The Rights will expire at 5:00 p.m. (Toronto time) on July 5, 2017 (the "Expiry Time"), after which time unexercised Rights will be void and of no value. Shareholders who fully exercise their Rights will be entitled to subscribe for additional Units, if available as a result of unexercised Rights prior to the Expiry Time, subject to certain limitations set out in the rights offering circular in respect of the Rights Offering (the "Circular"). Details of the Rights Offering will be set out in the rights offering notice (the "Notice") and Circular which will be available under APC's profile on SEDAR at www.sedar.com. The Notice and accompanying rights certificate (the "Rights Certificates") will be mailed to each eligible shareholder of the Company as at the Record Date. Registered shareholders who wish to exercise their Rights must forward the completed Rights Certificates, together with the applicable funds, to the rights agent, Computershare Investor Services Inc., on or before the Expiry Time. Shareholders who own their Common Shares through an intermediary, such as a bank, trust company, securities dealer or broker, will receive materials and instructions from their intermediary. Rights delivered to brokers, dealers or other intermediaries will not be delivered by those intermediaries to beneficial shareholders who are residents in a jurisdiction outside of Canada. The Company currently has 126,685,418 Common Shares outstanding. Assuming all the Rights issued under the Rights Offering are validly exercised, the Rights Offering will raise gross proceeds of approximately $1,900,281, the net proceeds of which will be used for debt repayment as well as working capital. The Closing Date is expected to occur on or about July 10, 2017. Any person who will own or control (beneficially or as nominee) more than 10 percent of the outstanding common shares of APC at closing of the Rights Offering must file a Personal Information Form ("PIF") with the Exchange and the Rights Offering will only close in escrow with respect of such person until the Exchange has notified the Company that the results of the review of the relevant PIFs are satisfactory. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United State3s or to, or for the account of benefit of, "U.S. persons", as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available. Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategies, plans or intentions. In particular, this news release contains forward-looking statements including, but not limited to, statements regarding the timing of, and other procedural matters associated with, the Rights Offering, and the use of proceeds from the Rights Offering. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


Jouvin L.,APC | Lemiere A.,APC | Terrier R.,APC
Proceedings of Science | Year: 2015

The center of our Galaxy hosts a Super-Massive Black Hole (SMBH) of about 4- 106 Msun. Since it has been argued that the SMBH might accelerate particles up to very high energies, its current and past activity could contribute to the population of Galactic cosmic-rays (CRs). Additionally, the condition in the Galactic Center (GC) are often compared with the one of a starburst system. The high supernovae (SN) rate associated with the strong massive star formation in the region must create a sustained CR injection in the GC via the shocks produced at the time of their explosion. Indeed, the presence of an excess of very high energy (VHE) cosmic rays in the inner 100 pc of the Galaxy has been revealed in 2006 by the H.E.S.S. collaboration. On very large scale (10 kpc), the non-thermal signature of the escaping GC cosmic rays could have been detected recently as the spectacular 'Fermi bubbles'. The origin of the CRs over-abundance in the GC still remains mysterious: Is it due to a single impulsive or stationary accelerator at the center or to multiple accelerators filling the region? In order to answer these questions, we build a 3D model of CR injection and propagation with a realistic 3D gas distribution. We then compare with existing data of H.E.S.S. We discuss the CR injection in the region by a spectral and morphology comparison. We place constrains on the SNR rate and on the diffusion parameters.


VANCOUVER, BC--(Marketwired - November 29, 2016) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) ( : 0E8) is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of labeling. The technology provides a means of sorting labeling entities according to the degree of selective labeling resulting from modification of a target antibody for conjugation. The methodology produces a rank order of candidate antibodies carrying antibody connectors for linkage to payloads such as drugs or toxins which should aid decision-making in ADC development. Immense growth is expected for the therapeutic antibody market which is estimated to reach nearly $125 Billion USD by the year 2020 (The therapeutic monoclonal antibody market: Ecker et al. MAbs 2015, Volume 7, ppgs 9-14.). This invention was developed to fulfil the Company's recently announced partnering initiatives with Wilex AG's subsidiary, Heidelberg Pharma GmbH and the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto. The method has been applied to measurements of the selectivity pattern that emerges from APC's experimental conditions for labeling commercially marketed antibody targets. Despite being prerequisites for a reliable assessment of performance of labeling technology, quantitative methods for the rapid determination of the purity of antibody-drug conjugates, and an analysis of the labeling pattern which produces them, have been lacking. APC's approach to impacting the field of antibody-drug conjugates is to design a labeling entity that places a handle on the antibody to which virtually any payload such as a drug or toxin can be attached. Since the Company is targeting "universal" sites on antibodies, the type that all IgG antibodies possess, it is important to emphasize that our approach could ultimately enable attaching drugs or toxins to any target antibody selectively, for which quantitative measurements are essential. (IgGs are the principal antibody carriers of ADCs.) Apropos of the above, APC is focusing on enabling technology, designed to link antibodies to drugs or toxins to produce pure and homogeneous antibody-drug conjugates. The field of antibody-drug conjugates affords numerous opportunities for improving the properties of therapeutic antibodies, but reliable methods for site-specifically attaching drugs or toxins to antibodies to give ADCs of high purity are needed to avoid the heterogeneity that currently limits applications of ADCs. The number of therapeutic antibodies and the companies producing them are legion, and growing, but comparatively few companies have capabilities for chemical modification of such antibodies aimed at producing "kinder and gentler" agents than classical chemotherapeutics. Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.


Stocchi F.,IRCCS San Raffaele | Borgohain R.,Nizam's Institute of Medical Sciences | Onofrj M.,University of Chieti Pescara | Schapira A.H.,University College London | And 4 more authors.
Movement Disorders | Year: 2012

Safinamide is an α-aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add-on to dopamine agonist (DA) therapy in early-stage PD. In this 24-week, double-blind study, patients with early PD receiving a stable dose of a single DA were randomized to once-daily safinamide 100 mg, safinamide 200 mg, or placebo. The primary efficacy variable was UPDRS part III (motor examination) total score. Analysis was hierarchical: 200 mg of safinamide versus placebo was tested first; the success of safinamide 100 mg versus placebo was contingent on this. Two hundred sixty-nine patients received safinamide 100 mg (n = 90), safinamide 200 mg (n = 89), or placebo (n = 90); 70, 81, and 81 patients, respectively, completed the study. Mean improvements from baseline to week 24 in UPDRS III total scores were -3.90 for safinamide 200 mg, -6.0 for safinamide 100 mg and -3.60 for placebo. The difference between safinamide 200 mg and placebo was not significant [point estimate: -0.4; 95% confidence interval (CI): -2.3-1.4; P = 0.6504]. Although the difference between 100 mg/day and placebo was significant (point estimate: -1.9; 95% CI: -3.7 to -0.1; P = 0.0419), these results are considered exploratory. No clinically meaningful differences from placebo were observed for any safety variables. This study did not demonstrate a significant improvement of the primary endpoint for safinamide 200 mg/day. Exploratory analysis of the primary endpoint for 100 mg/day demonstrated that the addition of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation. © 2011 Movement Disorder Society.


Cai Z.-Y.,International School for Advanced Studies | Cai Z.-Y.,Xiamen University | Lapi A.,International School for Advanced Studies | Lapi A.,University of Rome Tor Vergata | And 10 more authors.
Astrophysical Journal | Year: 2013

We present a comprehensive investigation of the cosmological evolution of the luminosity function of galaxies and active galactic nuclei (AGNs) in the infrared (IR). Based on the observed dichotomy in the ages of stellar populations of early-type galaxies on one side and late-type galaxies on the other, the model interprets the epoch-dependent luminosity functions at z ≥ 1.5 using a physical approach for the evolution of proto-spheroidal galaxies and of the associated AGNs, while IR galaxies at z < 1.5 are interpreted as being mostly late-type "cold" (normal) and "warm" (starburst) galaxies. As for proto-spheroids, in addition to the epoch-dependent luminosity functions of stellar and AGN components separately, we have worked out, for the first time, the evolving luminosity functions of these objects as a whole (stellar plus AGN component), taking into account in a self-consistent way the variation with galactic age of the global spectral energy distribution. The model provides a physical explanation for the observed positive evolution of both galaxies and AGNs up to z ≃ 2.5 and for the negative evolution at higher redshifts, for the sharp transition from Euclidean to extremely steep counts at (sub-)millimeter wavelengths, as well as the (sub-)millimeter counts of strongly lensed galaxies that are hard to account for by alternative, physical or phenomenological, approaches. The evolution of late-type galaxies and z < 1.5 AGNs is described using a parametric phenomenological approach. The modeled AGN contributions to the counts and to the cosmic infrared background (CIB) are always sub-dominant. They are maximal at mid-IR wavelengths: the contribution to the 15 and 24 μm counts reaches 20% above 10 and 2 mJy, respectively, while the contributions to the CIB are of 8.6% and of 8.1% at 15 μm and 24 μm, respectively. The model provides a good fit to the multi-wavelength (from the mid-IR to millimeter waves) data on luminosity functions at different redshifts and on number counts (both global and per redshift slices). A prediction of the present model, useful to test it, is a systematic variation with wavelength of the populations dominating the counts and the contributions to the CIB intensity. This implies a specific trend for cross-wavelength CIB power spectra, which is found to be in good agreement with the data. © 2013. The American Astronomical Society. All rights reserved.


Semikoz D.,APC
2009 CERN-Latin-American School of High-Energy Physics, CLASHEP 2009 - Proceedings | Year: 2010

In these three lectures I discuss the present status of high-energy astroparticle physics including Ultra-High-Energy Cosmic Rays (UHECR), high-energy gamma rays, and neutrinos. The first lecture is devoted to ultra-high-energy cosmic rays. After a brief introduction to UHECR I discuss the acceleration of charged particles to highest energies in the astrophysical objects, their propagation in the intergalactic space, recent observational results by the Auger and HiRes experiments, anisotropies of UHECR arrival directions, and secondary gamma rays produced by UHECR. In the second lecture I review recent results on TeV gamma rays. After a short introduction to detection techniques, I discuss recent exciting results of the H.E.S.S., MAGIC, and Milagro experiments on the point-like and diffuse sources of TeV gamma rays. A special section is devoted to the detection of extragalactic magnetic fields with TeV gammaray measurements. Finally, in the third lecture I discuss Ultra-High-Energy (UHE) neutrinos. I review three different UHE neutrino detection techniques and show the present status of searches for diffuse neutrino flux and point sources of neutrinos.


Binetruy P.,APC | Bohe A.,APC | Hertog T.,APC | Steer D.A.,APC
Physical Review D - Particles, Fields, Gravitation and Cosmology | Year: 2010

Junctions on cosmic string loops give rise to the proliferation of sharp kinks. We study the effect of this proliferation on the gravitational wave (GW) signals emitted from string networks with junctions, assuming a scaling solution. We calculate the rate of occurrence and the distribution in amplitude of the GW bursts emitted at cusps and kinks in the frequency bands of LIGO/VIRGO and LISA as a function of the string tension, the number of sharp kinks on loops with junctions, and the fraction of loops in the cosmological network which have junctions. Combining our results with current observational constraints, we find that pulsar data rule out a significant number of kinks on loops for strings with tensions Gμ10⊃-12. By contrast, for smaller tensions current observations allow for a large number of kinks on loops. If this is the case, the incoherent superposition of small bursts emitted at kink-kink encounters leads to an enhanced GW background that hides the strong individual bursts from kinks and cusps. © 2010 The American Physical Society.

Loading APC collaborators
Loading APC collaborators